In silico analysis of genomic landscape of SARS-CoV-2 and its variant of concerns (Delta and Omicron) reveals changes in the coding potential of miRNAs and their target genes.

Authors:
Saini S; Khurana S; Saini D; Rajput S; Thakur CJ and 5 more

Journal:
Gene

Publication Year: 2022

DOI:
10.1016/j.gene.2022.147097

PMCID:
PMC9721428

PMID:
36470485

Journal Information

Full Title: Gene

Abbreviation: Gene

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Molecular Biology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"appendix a supplementary material the following are the supplementary data to this article: supplementary data 1 sars-cov-2-reference pre-mirnas sequence data.; supplementary data 2 sars-cov-2-delta pre-mirnas sequence data.; supplementary data 3 sars-cov-2-omicron pre-mirnas sequence data.; supplementary data 4 secondary structures of predicted pre-mirnas.; supplementary data 5 target gene list of reference delta and omicron.; supplementary data 6 go and kegg pathway data of reference target genes.; supplementary data 7 go and kegg pathway data of delta target genes.; supplementary data 8 go and kegg pathway data of omicron target genes.; supplementary data 9 unique and common go and kegg pathway terms.; supplementary data 10 geo gene list of healthy vs mild sample.; supplementary data 11 geo gene list of healthy vs severe.; supplementary data 12 geo gene list of severe vs mild. data availability all data generated and analyzed during this study are included in the main manuscript and supplementary files . appendix a supplementary data to this article can be found online at https://doi"

Code Sharing
Evidence found in paper:

"Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

Evidence found in paper:

"Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025